KCTD9 Knockout DLD-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human DLD-1 colorectal adenocarcinoma cell line. This heterogeneous pool of knockout cells enables robust loss-of-function analyses of the KCTD9 gene, which encodes a substrate-specific adaptor for the cullin3-RING E3 ubiquitin ligase complex. By circumventing the biases of single-cell clones, the polyclonal format ensures that observed phenotypes reflect gene disruption rather than clonal artifacts, making it suitable for investigating KCTD9’s roles in ubiquitination, antiviral signaling, and cell cycle regulation.
The DLD-1 host cell line is a well-characterized model of colorectal adenocarcinoma, originally established from a primary tumor of a male patient. These adherent epithelial cells exhibit hallmark features of colorectal cancer, including aberrant signal transduction and oncogenic mutations, and are widely employed in cancer biology research for mechanistic studies and drug screening. The DLD-1 background provides a clinically relevant cellular context for studying KCTD9 function, particularly given the frequent dysregulation of ubiquitin ligase pathways in colorectal tumors.
KCTD9, a member of the KCTD protein family, acts as a substrate-specific adaptor for the CUL3-RBX1 E3 ubiquitin ligase complex, facilitating the ubiquitination and proteasomal degradation of target proteins. Notably, it mediates the degradation of TRIM25, a key component of the RIG-I-like receptor antiviral signaling pathway, thereby negatively regulating innate immune responses. In addition, KCTD9 interacts with CDK2 and p53, modulating cell cycle progression and apoptosis. Its expression is induced by type I interferons and is under the transcriptional control of p53, placing KCTD9 at a critical juncture between ubiquitin-dependent protein turnover, antiviral defense, and cell fate determination.
In the context of colorectal cancer, the KCTD9 knockout DLD-1 model enables in-depth investigation of the gene’s contributions to tumor cell proliferation, survival, and immune evasion. Disruption of KCTD9 allows researchers to probe its regulatory effects on CDK2/p53-dependent cell cycle checkpoints and apoptotic pathways, which are frequently disrupted in cancer. Moreover, the model can elucidate how KCTD9-mediated TRIM25 degradation influences innate immune signaling within the tumor microenvironment. The polyclonal knockout pool provides a genetically diverse population, enhancing the reliability and generalizability of functional analyses, and is particularly valuable for studying the role of ubiquitin ligase adaptors in colorectal cancer progression.
This knockout product is compatible with a wide array of experimental techniques. Researchers can employ RT-qPCR and western blotting to verify gene knockout and assess expression of downstream targets. Co-immunoprecipitation assays facilitate characterization of KCTD9’s interactions with CUL3, TRIM25, CDK2, and p53. Flow cytometry enables quantitative analysis of cell cycle distribution and apoptosis, while in vitro ubiquitination assays directly probe KCTD9-dependent protein degradation. Dual-luciferase reporter systems can measure KCTD9’s impact on NF-??B or interferon-stimulated response element activity. These applications make the KCTD9 Knockout DLD-1 Polyclonal Cells a powerful tool for research in colorectal cancer biology, ubiquitin signaling, and antiviral innate immunity. For further technical information, please contact Ascent Research.
